Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis

Apoptosis

Volumn 19, Issue 4, 2014, Pages 629-642

  Murphy, A C ^a   Weyhenmeyer, B ^a   Noonan, J ^a   Kilbride, S M ^a   Schimansky, S ^a   Loh, K P ^a   Kogel D ^b   Letai, A G ^c,d   Prehn, J H M ^a   Murphy, B M ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Glioblastoma; Mcl 1; R roscovitine; TRAIL

Indexed keywords

ACTIN; CASPASE 3; CASPASE 8; FLICE INHIBITORY PROTEIN; PROCASPASE 3; PROCASPASE 8; PROTEIN BID; PROTEIN MCL 1; PROTEIN NOXA; ROSCOVITINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; MCL1 PROTEIN, HUMAN; MYELOID LEUKEMIA FACTOR 1; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2; PURINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DISEASE RESISTANCE; DOWN REGULATION; ENZYME ACTIVATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NEUROMODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; GENE SILENCING; GLIOBLASTOMA; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; PURINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84896399808     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0935-2     Document Type: Article

References (58)

1. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
2. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479-489
3. Ruano Y et al (2008) Identification of survival-related genes of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma multiforme. Cancer 112(7):1575-1584
4. Strik H et al (1999) BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 67(6):763-768
5. Stegh AH et al (2007) Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21(1):98-111
6. Singh SK et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821-5828
7. Singh SK et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396-401
8. Altaner C (2008) Glioblastoma and stem cells. Neoplasma 55(5):369-374
9. Eramo A et al (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13(7):1238-1241
10. Bao S et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756-760
11. Lathia JD et al (2011) Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One 6(9):e24807
12. Murat A et al (2008) Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26(18):3015-3024
13. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281(5381):1305-1308
14. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2(6):420-430
15. Xiao C et al (2002) Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 277(28):25020-25025
16. Irmler M et al (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388(6638):190-195
17. Ashkenazi A et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104(2):155-162
18. Hao C et al (2001) Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 61(3):1162-1170
19. Kuijlen JM et al (2010) Review: on TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol 36(3):168-182
20. Fulda S, Meyer E, Debatin KM (2002) Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21(15):2283-2294
21. Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12(3):228-237
22. Hetschko H et al (2008) Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol 86(3):265-272
23. Henson ES et al (2003) Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J Cell Biochem 89(6):1177-1192
24. Taniai M et al (2004) Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 64(10):3517-3524
25. Zhang L et al (2011) Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Cell Death Differ 18(5):864-873
26. Yang T, Kozopas KM, Craig RW (1995) The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 128(6):1173-1184
27. Clohessy JG et al (2006) Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 281(9):5750-5759
28. Certo M et al (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9(5):351-365
29. Willis SN et al (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19(11):1294-1305
30. Chen L et al (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17(3):393-403
31. Ryan JA, Brunelle JK, Letai A (2010) Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4 + CD8 + thymocytes. Proc Natl Acad Sci USA 107(29):12895-12900
32. Duffin R et al (2009) The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1. FEBS Lett 583(15):2540-2546
33. Hallaert DY et al (2007) Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 14(11):1958-1967
34. Kim EH et al (2004) Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23(2):446-456
35. Henry CM, Hollville E, Martin SJ (2013) Measuring apoptosis by microscopy and flow cytometry. Methods 61(2):90-97
36. Nyga A, Cheema U, Loizidou M (2011) 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal 5(3):239-248
37. Quinn BA et al (2011) Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 20(10):1397-1411
38. Xu J, Liao X, Wong C (2010) Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer 126(4):1029-1035
39. Tagscherer KE et al (2008) Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27(52):6646-6656
40. Hetschko H et al (2008) Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. FEBS J 275(8):1925-1936
41. Ding L et al (2011) Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest 29(8):511-520
42. Unterkircher T et al (2011) Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 17(12):4019-4030
43. Jane EP, Premkumar DR, Pollack IF (2011) Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther 10(1):198-208
44. Bangert A et al (2012) Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 31(44):4677-4688
45. MacCallum DE et al (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65(12):5399-5407
46. Sallam H et al (2008) Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain. Pharmacol Res 58(1):32-37
47. Leitch AE et al (2010) The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis. Eur J Immunol 40(4):1127-1138
48. Farahi N et al (2011) Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance. Clin Exp Allergy 41(5):673-687
49. Brooks AD, Sayers TJ (2005) Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 54(5):499-505
50. Ortiz-Ferron G et al (2008) Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 18(6):664-676
51. Rudner J et al (2005) Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies. Oncogene 24(1):130-140
52. Peter ME, Krammer PH (2003) The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10(1):26-35
53. Aldridge BB et al (2011) Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis. Mol Syst Biol 7:553
54. Huang Q et al (2011) Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 17(7):860-866
55. Lucas KM et al (2012) Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res 18(3):783-795
56. Premkumar DR et al (2011) Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog 52(2):118-133
57. Gomez-Bougie P et al (2007) Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67(11):5418-5424
58. Han J et al (2006) Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 281(15):10153-10163